- Language: English
- 572 Pages
- Published: November 2012
- Region: World
Global Hyperphosphatemia Drugs Market 2011-2015
- Published: July 2012
- 37 pages
- Infiniti Research Limited
TechNavio's analysts forecast the Global Hyperphosphatemia Drugs market to grow at a CAGR of 12.5 percent over the period 2011-2015. One of the key factors contributing to this market growth is the increasing prevalence of chronic kidney disease. The Global Hyperphosphatemia Drugs market has also been witnessing the trend of an increasing number of strategic alliances among vendors. However, side effects caused by the hyperphosphatemia drugs could pose a challenge to the growth of this market.
TechNavio's report, the Global Hyperphosphatemia Drugs Market 2011-2015, has been prepared based on an in-depth analysis of the market with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Hyperphosphatemia Drugs market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors dominating this market space include Fresenius Medical Care AG & Co. KGaA, Shire plc, and Sanofi S.A.
Other vendors mentioned in the report: Keryx Biopharmaceuticals Inc., Novartis AG, Vifor Pharma AG, Astellas Pharma Inc., Panacor Bioscience Ltd., and Perrigo Co.
Key questions answered in this report:
What will the market size be in 2015 and at what rate will it grow?
What key trends is this market subject to?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
What are the opportunities and threats faced by each of these key vendors?
What are the strengths and weaknesses of each of these key vendors?
You can request one free hour of analyst time when you purchase this report. Details provided within the report.
TechNavio today launched its report Global Hyperphosphatemia Drugs Market 2011-2015 based on an in-depth study covering the Americas, and the EMEA and APAC regions. The report aims to aid decision makers’ understanding of the present and future landscape of the market.
Commenting on the report, an analyst from TechNavio’s Healthcare team said; “The Global Hyperphosphatemia Drugs market provides enough growth opportunity for vendors because of the increasing demand for phosphate binders in chronic kidney disease (CKD) and hyperphosphatemia treatments. Since iron-based phosphate binders have better phosphate-binding capacity, vendors in the market are investing heavily in R&D to develop iron-based phosphate binders for the treatment of hyperphosphatemia in end-stage renal disease patients.”
According to the report, there is an increase in the prevalence of CKD across the world, and CKD is one of the main causes of hyperphosphatemia. Thus, the increasing prevalence of kidney diseases will drive the Global Hyperphosphatemia Drugs market.
Further, the report also discusses that the biggest challenge that the Global Hyperphosphatemia Drugs market is facing is the side effects caused by currently used phosphate binders.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key players. SHOW LESS READ MORE >
01. Executive Summary
03. Market Coverage
04. Market Landscape
Five Forces AnalysiS
05. Geographical Segmentation
06. Key Leading Countries
Economic Indicators of Key Leading Countries
07. Rate of Incidence and Prevalence
08. Vendor Landscape
09. Buying Criteria
10. Market Growth Drivers
11. Drivers and their Impact
12. Market Challenges
13. Impact of Drivers and Challenges
14. Market Trends
15. Key Vendor Analysis
15.1 Sanofi S.A.
15.2 Shire plc.
15.3 Fresenius Medical Care AG & Co. KGaA
16. Other Reports in this Series
List of Exhibits:
Exhibit 1: Global Hyperphosphatemia Drugs Market 2011-2015 (US$ million)
Exhibit 2: Global Hyperphosphatemia Drugs Market by Geographical Segmentation 2011
Exhibit 3: Global Hyperphosphatemia Drugs Market by Vendor Segmentation 2011
Fresenius Medical Care AG & Co. KGaA, Shire plc, Sanofi S.A
|Electronic (PDF)||The report will be emailed to you. The report is sent in PDF format.||This is a single user license, allowing one specific user access to the product.|
|1 - 5 Users||The report will be emailed to you. The report is sent in PDF format.||This is a 1-5 user licence, allowing up to five users have access to the product.|
|Enterprisewide||The report will be emailed to you. The report is sent in PDF format.||This is an enterprise license, allowing all employees within your organisation access to the product.|